CTOs on the Move


 
SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.syngeninc.com
  • 2125 19th St Suite 120
    Sacramento, CA USA 95818
  • Phone: 916.706.0923

Executives

Name Title Contact Details

Similar Companies

Microfil

Microfil LLC is a Bridgman, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ROWI

ROWI Teen is a mental health treatment center for teens and adolescents, specializing in mental health issues like depression, anxiety, OCD, and ASD.

A-S-K PharmMed Associates

A-S-K PharmMed Associates, Inc. is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

TargetRx

TargetRx is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.